3BNC117: Phase I data

An open-label, dose-escalation, U.S. and German Phase I trial in 17 patients with HIV-1 infection and 12 uninfected subjects showed that single doses of 1, 3, 10 and 30 mg/kg IV 3BNC117 were generally...